ViroGates A/S
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital clinics to guide and inform individuals of their health state, and in hospitals to support clinical decisions and identify high-risk patients, as well as used for a range of acute and chronic he… Read more
Market Cap & Net Worth: ViroGates A/S (VIRO)
ViroGates A/S (CO:VIRO) has a market capitalization of $14.50 Million (Dkr105.35 Million) as of March 19, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #31097 globally and #97 in its home market, demonstrating a -4.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ViroGates A/S's stock price Dkr11.35 by its total outstanding shares 9281891 (9.28 Million).
ViroGates A/S Market Cap History: 2018 to 2026
ViroGates A/S's market capitalization history from 2018 to 2026. Data shows change from $76.65 Million to $14.50 Million (-22.99% CAGR).
ViroGates A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ViroGates A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.77x
ViroGates A/S's market cap is 2.77 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $76.65 Million | $3.32 Million | -$16.99 Million | 23.11x | N/A |
| 2019 | $43.82 Million | $3.58 Million | -$18.80 Million | 12.23x | N/A |
| 2020 | $104.11 Million | $5.35 Million | -$18.74 Million | 19.45x | N/A |
| 2021 | $183.96 Million | $7.66 Million | -$17.66 Million | 24.03x | N/A |
| 2022 | $51.23 Million | $15.20 Million | -$9.65 Million | 3.37x | N/A |
| 2023 | $7.69 Million | $6.99 Million | -$12.10 Million | 1.10x | N/A |
| 2024 | $13.54 Million | $4.90 Million | -$14.35 Million | 2.77x | N/A |
Competitor Companies of VIRO by Market Capitalization
Companies near ViroGates A/S in the global market cap rankings as of March 19, 2026.
Key companies related to ViroGates A/S by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #84 globally with a market cap of $187.53 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #151 globally with a market cap of $119.88 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #170 globally with a market cap of $111.60 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #183 globally with a market cap of $105.38 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #84 | Abbott Laboratories | NYSE:ABT | $187.53 Billion | $108.49 |
| #151 | Stryker Corporation | NYSE:SYK | $119.88 Billion | $345.81 |
| #170 | Medtronic PLC | NYSE:MDT | $111.60 Billion | $87.21 |
| #183 | Boston Scientific Corp | NYSE:BSX | $105.38 Billion | $71.28 |
ViroGates A/S Historical Marketcap From 2018 to 2026
Between 2018 and today, ViroGates A/S's market cap moved from $76.65 Million to $ 14.50 Million, with a yearly change of -22.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr14.50 Million | -15.61% |
| 2025 | Dkr17.18 Million | +26.89% |
| 2024 | Dkr13.54 Million | +76.08% |
| 2023 | Dkr7.69 Million | -84.99% |
| 2022 | Dkr51.23 Million | -72.15% |
| 2021 | Dkr183.96 Million | +76.69% |
| 2020 | Dkr104.11 Million | +137.61% |
| 2019 | Dkr43.82 Million | -42.83% |
| 2018 | Dkr76.65 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of ViroGates A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.50 Million USD |
| MoneyControl | $14.50 Million USD |
| MarketWatch | $14.50 Million USD |
| marketcap.company | $14.50 Million USD |
| Reuters | $14.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.